The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival.

Détails

ID Serval
serval:BIB_2714D13FF96C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival.
Périodique
Oral oncology
Auteur(s)
Turri-Zanoni M., Maragliano R., Battaglia P., Giovannardi M., Antognoni P., Lombardi D., Morassi M.L., Pasquini E., Tarchini P., Asioli S., Foschini M.P., Sessa F., Nicolai P., Castelnuovo P., La Rosa S.
ISSN
1879-0593 (Electronic)
ISSN-L
1368-8375
Statut éditorial
Publié
Date de publication
11/2017
Peer-reviewed
Oui
Volume
74
Pages
21-29
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
To provide a comprehensive review of the clinical and histopathological features of olfactory neuroblastoma (ONB) and other sinonasal neuroendocrine neoplasms (NENs), in order to refine diagnostic criteria, analyze treatment outcomes, and identify prognostic factors.
Data from an Italian multi-institutional database were analyzed. Patients were treated surgically via a minimally-invasive endoscopic approach followed by adjuvant radiotherapy or radiochemotherapy. Neoadjuvant cisplatin/etoposide chemotherapy was administered in cases of poorly-differentiated tumors. A centralized pathology review was performed in all cases. Patients were prospectively observed for survival. Overall (OS) and Disease-free survival (DFS) estimates were determined from Kaplan-Meier analysis and compared using the log-rank test. Statistically significant variables were entered in a multivariate Cox regression model.
98 patients with a median follow-up of 53months were included. Morphology review and the incorporation of cytokeratin 8/18 in the immunohistochemical panel modified the final diagnosis in 8/98 (8.2%) cases. The neoplasms were ultimately classified into four groups with different immunohistochemical profiles and clinical behaviors: ONB in 67 cases (5-year-OS, 91.6%); NEC (poorly-differentiated neuroendocrine carcinoma) in 22 cases (5-year-OS, 42.6%); MiNEN (mixed neuroendocrine/non-neuroendocrine neoplasm) in five cases (5-year-OS, 0%,0/5 cases); and NET (well-differentiated neuroendocrine tumor) in four cases (5-year-OS, 50%, 2/4 cases). Hyams grade and Ki67 index were independent prognostic factors for ONB. Neoadjuvant chemotherapy appeared to be associated with improved OS and DFS for NEC, independent of other clinicopathological variables.
Induction chemotherapy improves survival outcomes in patients affected by poorly-differentiated tumors. Recent advances in histopathological diagnosis, including CK8/18 staining, allow to plan the most appropriate range of multimodal treatments.
Mots-clé
Adolescent, Adult, Aged, Combined Modality Therapy, Esthesioneuroblastoma, Olfactory/diagnosis, Esthesioneuroblastoma, Olfactory/metabolism, Esthesioneuroblastoma, Olfactory/pathology, Esthesioneuroblastoma, Olfactory/therapy, Female, Humans, Immunohistochemistry, Ki-67 Antigen/metabolism, Male, Middle Aged, Nasal Cavity/pathology, Nose Neoplasms/diagnosis, Nose Neoplasms/metabolism, Nose Neoplasms/pathology, Nose Neoplasms/therapy, Prognosis, Survival Analysis, Young Adult, Cytokeratin, Esthesioneuroblastoma, Ki67, Nasal cavity, Neuroendocrine carcinoma, Olfactory neuroblastoma, Paranasal sinuses
Pubmed
Web of science
Création de la notice
07/11/2017 14:18
Dernière modification de la notice
20/08/2019 13:05
Données d'usage